Plasma Metabolic Analysis Reveals the Dysregulation of Short-Chain Fatty Acid Metabolism in Parkinson’s Disease

[1]  Vasco A Conceição,et al.  Serum Phospholipid Profile Changes in Gaucher Disease and Parkinson’s Disease , 2022, International journal of molecular sciences.

[2]  Junwu Zhao,et al.  Blood neuroexosomal excitatory amino acid transporter-2 is associated with cognitive decline in Parkinson’s disease with RBD , 2022, Frontiers in Aging Neuroscience.

[3]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[4]  Hsiang-Yu Tang,et al.  Alterations of Sphingolipid and Phospholipid Pathways and Ornithine Level in the Plasma as Biomarkers of Parkinson’s Disease , 2022, Cells.

[5]  Yu-Wei Wu,et al.  Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease , 2022, Neurology.

[6]  Ilona B. Bruinsma,et al.  Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach , 2021, NPJ Parkinson's disease.

[7]  Yusen Chen,et al.  Targeted fatty acid metabolomics to discover Parkinson's disease associated metabolic alteration. , 2021, Journal of Mass Spectrometry.

[8]  Sonja W. Scholz,et al.  Challenges in the diagnosis of Parkinson's disease , 2021, The Lancet Neurology.

[9]  Q. Xiao,et al.  Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson's Disease. , 2021, Journal of Parkinson's disease.

[10]  J. Wells,et al.  Microbial Regulation of Host Physiology by Short-chain Fatty Acids. , 2021, Trends in microbiology.

[11]  Weiqing Wang,et al.  Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease , 2021, Microbiome.

[12]  D. Devos,et al.  Glycosphingolipids and neuroinflammation in Parkinson’s disease , 2020, Molecular Neurodegeneration.

[13]  F. Valldeoriola,et al.  Peripheral insulin and amylin levels in Parkinson's disease. , 2020, Parkinsonism & related disorders.

[14]  Hyewon Lim,et al.  Plasma Short‐Chain Fatty Acids in Patients With Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[15]  R. Frozza,et al.  The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication , 2020, Frontiers in Endocrinology.

[16]  S. Aoki,et al.  A metabolic profile of polyamines in parkinson disease: A promising biomarker , 2019, Annals of neurology.

[17]  Chin-Hsien Lin,et al.  Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease , 2019, Journal of movement disorders.

[18]  C. Consolandi,et al.  Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism , 2018, Movement disorders : official journal of the Movement Disorder Society.

[19]  Hugo J. Bellen,et al.  Sphingolipids in the Pathogenesis of Parkinson’s Disease and Parkinsonism , 2019, Trends in Endocrinology & Metabolism.

[20]  Cheng Peng,et al.  Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines , 2018, Front. Pharmacol..

[21]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[22]  Kassem M. Makki,et al.  The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. , 2018, Cell host & microbe.

[23]  B. Pakkenberg,et al.  Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977–2014 , 2018, Gut.

[24]  James T. Morton,et al.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome , 2017, Movement disorders : official journal of the Movement Disorder Society.

[25]  K. Fassbender,et al.  Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. , 2016, Parkinsonism & related disorders.

[26]  F. Bäckhed,et al.  From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites , 2016, Cell.

[27]  R. Aminov,et al.  Systemic Concentrations of Short Chain Fatty Acids Are Elevated in Salmonellosis and Exacerbation of Familial Mediterranean Fever , 2016, Front. Microbiol..

[28]  M. Cersosimo.  Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease , 2015, Gastroenterology research and practice.

[29]  M. Heymann,et al.  Structural alterations of the intestinal epithelial barrier in Parkinson’s disease , 2015, Acta neuropathologica communications.

[30]  A. Rajput,et al.  Accuracy of Parkinson disease diagnosis unchanged in 2 decades , 2014, Neurology.

[31]  Huidong Shi,et al.  Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. , 2014, Immunity.

[32]  A. Rudensky,et al.  Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.

[33]  K. Shannon,et al.  Is alpha‐synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases , 2012, Movement disorders : official journal of the Movement Disorder Society.

[34]  P. Derkinderen,et al.  Parkinson Disease: The Enteric Nervous System Spills its Guts , 2012, Neurology.

[35]  J. Greene,et al.  Gastrointestinal Features of Parkinson’s Disease , 2011, Current neurology and neuroscience reports.

[36]  H. Braak,et al.  Parkinson's Disease , 2009, Annals of the New York Academy of Sciences.

[37]  A. Probst,et al.  α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects , 2006, Neuropathology and applied neurobiology.

[38]  G. Macfarlane,et al.  Short chain fatty acids in human large intestine, portal, hepatic and venous blood. , 1987, Gut.